Psoriatic Arthritis

Researchers have identified several clinical characteristics of psoriasis patients that may increase the risk of developing psoriatic arthritis.  A single-center, retrospective cohort study examined the clinical profiles of psoriasis patients to determine the precursors of psoriatic arthritis (PsA), aiming to bridge the gap between psoriasis management and the identification of psoriatic arthritis risk. The study’s...

Guselkumab, a targeted inhibitor of interleukin-23, has emerged as a promising therapy for psoriatic arthritis, offering hope for improved patient outcomes.  A prospective multicenter study aimed to shed light on the effectiveness of using guselkumab for psoriatic arthritis (PsA) management by analyzing the experiences of PsA patients over 6 months. The study also looked at...

Newly published data from a prospective cohort study indicate that diagnosing psoriatic arthritis within 12 weeks after symptom onset may represent a clinical window of opportunity for achieving minimal disease activity and disease remission.  In rheumatoid arthritis, the benefits of early treatment within 12 weeks following symptom onset are well-documented, leading to better remission rates,...

An analysis of microarray data demonstrated impaired apoptosis signaling pathways in CD14+ monocytes in psoriatic arthritis patients, concluding that their increased levels may play an essential role in the disease pathogenesis. Psoriatic arthritis (PsA) is a complex chronic inflammatory condition affecting approximately 30% of patients with psoriasis, leading to functional impairments and increased mortality risk. ...

A prospective follow-up study found that psoriatic arthritis patients with higher synovial immunohistochemical reactivity of IL-17A, DKK1, and TGF-β1 are more likely to benefit from early initiation of biologics. Psoriatic arthritis (PsA) is a chronic inflammatory disease affecting joints and skin in patients with psoriasis. It exhibits progressive and destructive joint changes, with significant pathological...

Although psoriatic arthritis activity indices might suggest disease severity, this retrospective study demonstrated that disease activity levels and severity are two different concepts and not essentially interchangeable. Psoriatic arthritis (PsA) is a complex, chronic, multidomain inflammatory disease. There have been many studies and indices focusing on identifying and classifying disease activity levels. However, much less...

Bimekizumab demonstrates overall greater efficacy than guselkumab in psoriatic arthritis patients at 52 weeks, according to an analysis of data from several trials. Approximately 30% of psoriasis patients develop psoriatic arthritis (PsA). Recent Phase 3 trials have demonstrated the efficacy and safety of bimekizumab (an interleukin-17F and IL-17A inhibitor) and guselkumab (an interleukin-23 inhibitor) in...

A phase 3 study of risankizumab finds durable long-term efficacy and a stable safety profile in patients with active psoriatic arthritis. Psoriatic arthritis (PsA) affects approximately 0.05–0.25% of the general population and 6–41% of psoriasis patients. As most PsA patients do not maintain minimal disease activity on current therapies, there is a need for effective...

Fecal microbiota transplantation affects several inflammation-associated plasma proteins in psoriatic arthritis, suggesting systemic immune response induction, according to a recent exploratory study. Psoriatic arthritis (PsA) is an immune-mediated disease associated with alterations in the gut microbial environment. As the gut microbiota can mediate inflammatory responses, one potential intervention for PsA is fecal microbiota transplantation (FMT)....